Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 30.03.2020 | 09:00

Aladdin Healthcare Technologies SE launches its prototype 'Health Risk Assessment Tool' for COVID-19 in India - The Technology is the basis for worldwide application

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Product Launch
30.03.2020 / 09:00
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies SE launches its prototype 'Health Risk Assessment Tool' for COVID-19 in India - The Technology is the basis for worldwide application

BERLIN/LONDON, March 30, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2) pushes forward the development of the prototype image segmentation cloud platform. This technology serves as "Health Risk Assessment Tool" (HRA) to assist the diagnosis of COVID-19 Coronavirus.

Aladdin has built a Health Risk Assessment Tool (HRA) as web and mobile application to manage risk assessment in connection to COVID-19 for global use. The HRA tool combines both artificial intelligence (AI) and augmented reality (AR) and opens up new opportunities in the management of COVID-19 risks for companies and private persons. Aladdin will first launch the technology in India. The tool is expected to be available on the market and than introduced in other countries by the end of the second quarter 2020.

More specifically, the AI application provides users with a real time risk assessment of individuals infected with coronavirus. In addition, the application is able to take further steps in their treatment. For example, it shows whether doctors are available for video consultations and the nearest available hospital for treatment. At the same time, the AI suggests suitable further care measures and gives lifestyle advice.

Aladdin has long been active in the important Indian market. Together with the OurHealthMate's (OHM) medical platform, Aladdin has already built a diabetic and cardiovascular risk prediction tool in India. In addition, Aladdin's services are now being used by several Fortune 500 companies in the healthcare management. OHM will also integrate the risk assessment platform into its ecosystem, that will enable Aladdin's application to be accessed by over 2,000 plus healthcare partners. These include major hospital operators and health insurance companies.

Aladdin and OHM have already agreed to share revenues from this collaboration in half, beginning in the second quarter 2020.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE commented: "Aladdin is building a global collaboration team to enhance its CT AI platform for global use. By validating it through multiple international patient data sets of COVID-19 patients, we have set out to create a new gold standard for COVID 19 testing. AI-based systems are a great chance in personalised medicine. They enable a much more efficient treatment process. With our HRA tool, we can make an important contribution in the fight against coronavirus and COVID-19."

A public offering of shares in the company is open and will run from 9 to 30 March 2020. Further information is available at:

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer's disease, with the technology also being applied to other indications such as COVID-19 Coronavirus. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by the award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, the AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330

30.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.


Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

Continental AG: Die Continental AG hat beschlossen, den Gewinnverwendungsvorschlag für die Hauptversammlung am 14. Juli 2020 auf 3,00 Euro pro Aktie anzupassen

03. Juni 2020, 11:28

Aktuelle Research-Studie

DEAG Deutsche Entertainment Aktiengesellschaft

Original-Research: DEAG Deutsche Entertainment AG (von Montega AG): Buy

03. Juni 2020